Teva Pharmaceuticals Class II Drug Recall - Metoprolol Succinate
Summary
The FDA has initiated a Class II drug recall for Teva Pharmaceuticals' Metoprolol Succinate Extended-Release Tablets due to failed dissolution specifications. The recall affects product distributed nationwide and is ongoing.
What changed
The Food and Drug Administration (FDA) has issued a Class II drug recall for Teva Pharmaceuticals USA, Inc.'s Metoprolol Succinate Extended-Release Tablets (100 mg). The recall, identified by docket number D-0356-2026, is due to the product failing to meet dissolution specifications. This recall impacts product distributed nationwide.
Pharmaceutical manufacturers and distributors must immediately identify and quarantine affected Metoprolol Succinate Extended-Release Tablets. Companies should follow their established recall procedures and coordinate with Teva Pharmaceuticals and the FDA regarding the disposition of recalled product. Failure to comply with recall procedures can result in regulatory action.
What to do next
- Identify and quarantine affected Metoprolol Succinate Extended-Release Tablets.
- Follow established recall procedures for product disposition.
- Coordinate with Teva Pharmaceuticals and the FDA on recall execution.
Archived snapshot
Mar 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Teva Pharmaceuticals USA, Inc
Drug Recalls (Class II)
← All Drug Recalls (Class II) Class II D-0356-2026 · 20260311 · Ongoing
Product
Metoprolol Succinate Extended-Release Tablets, Rx Only, 100 mg, 100 tablets bottles (NDC: 45963-677-11) and 1,000 tablets bottles (NDC: 45963-677-96), Teva Pharmaceuticals, Parsippany, NJ 07054.
Reason for Recall
Failed Dissolution Specifications
Distribution
Nationwide
Source: openFDA Enforcement API
Related changes
Get daily alerts for FDA: Drug Recalls Class II
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when FDA: Drug Recalls Class II publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.